Cost-effectiveness analysis of in silico clinical trials of vascular stents

2021 IEEE 21st International Conference on Bioinformatics and Bioengineering (BIBE) Pub Date : 2021-10-25 DOI:10.1109/BIBE52308.2021.9635321

M. Gacic, Milica Kaplarevic, N. Filipovic

{"title":"Cost-effectiveness analysis of in silico clinical trials of vascular stents","authors":"M. Gacic, Milica Kaplarevic, N. Filipovic","doi":"10.1109/BIBE52308.2021.9635321","DOIUrl":null,"url":null,"abstract":"The world stent market has an estimated value of €6.4 billion, of which 37% is generated in the US and 10% in the EU. Coronary stents are now the most commonly implanted medical devices, with more than 1 million implanted annually. Coronary stents are currently the most widely used for treating symptomatic coronary disease. In this study, the traditional approach for today's clinical trials with only 10% success rate was described. Within the EU funded project InSilc (www.insilc.eu) was developed the innovative platform for designing, developing and assessing coronary stents. It consists of separate modules and some of them can be used as a standalone tool. Description of each module was given. Cost-effectiveness analysis described the calculation method of the prices of each module as well as platform as a whole, per one stent simulation. The average cost per patient for the execution of a real clinical trial was calculated. The calculated price for in silico trials is below breakeven point in comparison to real clinical trial.","PeriodicalId":343724,"journal":{"name":"2021 IEEE 21st International Conference on Bioinformatics and Bioengineering (BIBE)","volume":"40 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"2021 IEEE 21st International Conference on Bioinformatics and Bioengineering (BIBE)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1109/BIBE52308.2021.9635321","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

The world stent market has an estimated value of €6.4 billion, of which 37% is generated in the US and 10% in the EU. Coronary stents are now the most commonly implanted medical devices, with more than 1 million implanted annually. Coronary stents are currently the most widely used for treating symptomatic coronary disease. In this study, the traditional approach for today's clinical trials with only 10% success rate was described. Within the EU funded project InSilc (www.insilc.eu) was developed the innovative platform for designing, developing and assessing coronary stents. It consists of separate modules and some of them can be used as a standalone tool. Description of each module was given. Cost-effectiveness analysis described the calculation method of the prices of each module as well as platform as a whole, per one stent simulation. The average cost per patient for the execution of a real clinical trial was calculated. The calculated price for in silico trials is below breakeven point in comparison to real clinical trial.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

血管支架计算机临床试验的成本-效果分析

世界支架市场估计价值64亿欧元，其中37%来自美国，10%来自欧盟。冠状动脉支架是目前最常见的植入式医疗器械，每年植入式超过100万例。冠状动脉支架是目前治疗症状性冠状动脉疾病最广泛的方法。在本研究中，描述了当今临床试验只有10%成功率的传统方法。在欧盟资助的项目中，InSilc (www.insilc.eu)开发了用于设计、开发和评估冠状动脉支架的创新平台。它由独立的模块组成，其中一些模块可以作为独立工具使用。给出了各个模块的描述。成本效益分析描述了各个模块以及平台整体价格的计算方法，每个支架的仿真。计算了执行实际临床试验的每位患者的平均成本。与真正的临床试验相比，计算机试验的计算价格低于盈亏平衡点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

2021 IEEE 21st International Conference on Bioinformatics and Bioengineering (BIBE)

自引率

0.00%

发文量